Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2009

01.05.2009 | Short Communication

Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction

verfasst von: Gondi Kumar, Henry Lau, Oscar Laskin

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the potential for drug–drug interactions between lenalidomide and substrates and inhibitors of cytochrome P450 (CYP) isozymes.

Methods

In vitro metabolism of lenalidomide by human liver microsomes, recombinant human CYPs and human hepatocytes was evaluated. The inhibitory and inductive effects of lenalidomide on the CYP activities were evaluated in human liver microsomes and cultured human hepatocytes, respectively.

Results

In vitro incubation of lenalidomide with human liver microsomes, recombinant-CYP isozymes, and human hepatocytes did not result in Phase I or Phase II metabolism, confirming the low propensity of lenalidomide for metabolism in vivo in humans. In vitro, lenalidomide did not inhibit CYP isozymes in human liver microsomes and did not induce CYP activities in cultured human hepatocytes.

Conclusions

Lenalidomide is not a substrate, inhibitor, or inducer of CYP group of enzymes; clinically relevant pharmacokinetic drug–drug interactions are unlikely to occur between lenalidomide and co-administered CYP substrates or inhibitors.
Literatur
1.
Zurück zum Zitat Schafer PH, Gandhi AK, Loveland MA et al (2003) Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 305(3):1222–1232PubMedCrossRef Schafer PH, Gandhi AK, Loveland MA et al (2003) Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 305(3):1222–1232PubMedCrossRef
2.
Zurück zum Zitat Gandhi AK, Kang J, Naziruddin S et al (2006) Lenalidomide inhibits proliferation of Namalwa CSN. 70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 30(7):849–858PubMedCrossRef Gandhi AK, Kang J, Naziruddin S et al (2006) Lenalidomide inhibits proliferation of Namalwa CSN. 70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 30(7):849–858PubMedCrossRef
3.
Zurück zum Zitat List A, Kurtin S, Roe DJ et al (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352(6):549–557PubMedCrossRef List A, Kurtin S, Roe DJ et al (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352(6):549–557PubMedCrossRef
4.
Zurück zum Zitat Melchert M, Kale V, List A (2007) The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol 14(2):123–129PubMedCrossRef Melchert M, Kale V, List A (2007) The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol 14(2):123–129PubMedCrossRef
5.
Zurück zum Zitat Richardson PG, Blood E, Mitsiades CS et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108(10):3458–3464PubMedCrossRef Richardson PG, Blood E, Mitsiades CS et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108(10):3458–3464PubMedCrossRef
6.
Zurück zum Zitat Rajkumar SV, Hayman SR, Lacy MQ et al (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106(13):4050–4053PubMedCrossRef Rajkumar SV, Hayman SR, Lacy MQ et al (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106(13):4050–4053PubMedCrossRef
7.
Zurück zum Zitat Thomas S, Alexanian R (2007) Current treatment strategies for multiple myeloma. Clin Lymphoma Myeloma 7(suppl 4):S139–S144PubMedCrossRef Thomas S, Alexanian R (2007) Current treatment strategies for multiple myeloma. Clin Lymphoma Myeloma 7(suppl 4):S139–S144PubMedCrossRef
8.
Zurück zum Zitat Molica S (2007) Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm. Leuk Lymphoma 48(5):866–869PubMedCrossRef Molica S (2007) Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm. Leuk Lymphoma 48(5):866–869PubMedCrossRef
9.
Zurück zum Zitat Dreicer R (2007) Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors. Curr Oncol Rep 9(2):120–123PubMedCrossRef Dreicer R (2007) Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors. Curr Oncol Rep 9(2):120–123PubMedCrossRef
10.
Zurück zum Zitat Chanan-Khan AA, Cheson BD (2008) Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 26(9):1544–1552PubMedCrossRef Chanan-Khan AA, Cheson BD (2008) Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 26(9):1544–1552PubMedCrossRef
11.
Zurück zum Zitat Back DJ, Orme ML (1990) Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 18(6):472–484PubMedCrossRef Back DJ, Orme ML (1990) Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 18(6):472–484PubMedCrossRef
12.
Zurück zum Zitat Park BK, Kitteringham NR, Pirmohamed M et al (1996) Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol 41(6):477–491PubMedCrossRef Park BK, Kitteringham NR, Pirmohamed M et al (1996) Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol 41(6):477–491PubMedCrossRef
13.
Zurück zum Zitat Gentile DM, Tomlinson ES, Maggs JL et al (1996) Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 277(1):105–112PubMed Gentile DM, Tomlinson ES, Maggs JL et al (1996) Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 277(1):105–112PubMed
14.
Zurück zum Zitat Pascussi JM, Drocourt L, Fabre JM et al (2000) Dexamethasone induces pregnane X receptor and retinoid X receptor—alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 58(2):361–372PubMed Pascussi JM, Drocourt L, Fabre JM et al (2000) Dexamethasone induces pregnane X receptor and retinoid X receptor—alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 58(2):361–372PubMed
15.
Zurück zum Zitat LeCluyse E, Madan A, Hamilton G et al (2000) Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14(4):177–188PubMedCrossRef LeCluyse E, Madan A, Hamilton G et al (2000) Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14(4):177–188PubMedCrossRef
16.
Zurück zum Zitat Madan A, Graham RA, Carroll KM et al (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31(4):421–431PubMedCrossRef Madan A, Graham RA, Carroll KM et al (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31(4):421–431PubMedCrossRef
17.
Zurück zum Zitat Quistorff B, Dich J, Grunnet N (1989) Preparation of isolated rat liver hepatocytes. In: Pollard JW, Walker JM (eds) Methods in molecular biology, vol 5. Animal cell culture. Humana Press, New Jersey, pp 151–160 Quistorff B, Dich J, Grunnet N (1989) Preparation of isolated rat liver hepatocytes. In: Pollard JW, Walker JM (eds) Methods in molecular biology, vol 5. Animal cell culture. Humana Press, New Jersey, pp 151–160
18.
Zurück zum Zitat Chen N, Lau H, Kong L et al (2007) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47(12):1466–1475PubMedCrossRef Chen N, Lau H, Kong L et al (2007) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47(12):1466–1475PubMedCrossRef
Metadaten
Titel
Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction
verfasst von
Gondi Kumar
Henry Lau
Oscar Laskin
Publikationsdatum
01.05.2009
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2009
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0867-7

Weitere Artikel der Ausgabe 6/2009

Cancer Chemotherapy and Pharmacology 6/2009 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.